Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Preferred Stock Liabilities (2020)

Historic Preferred Stock Liabilities for Janux Therapeutics (JANX) over the last 1 years, with Q4 2020 value amounting to $21.6 million.

  • Janux Therapeutics' Preferred Stock Liabilities changed N/A to $21.6 million in Q4 2020 from the same period last year, while for Dec 2020 it was $21.6 million, marking a year-over-year change of. This contributed to the annual value of $21.6 million for FY2020, which is N/A changed from last year.
  • Per Janux Therapeutics' latest filing, its Preferred Stock Liabilities stood at $21.6 million for Q4 2020.
  • Janux Therapeutics' 5-year Preferred Stock Liabilities high stood at $21.6 million for Q4 2020, and its period low was $21.6 million during Q4 2020.